VIA
NGNE icon

Virtus Investment Advisers’s Neurogene NGNE Stock Holding History

Virtus Investment Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Buy
13,033
+317
+2% +$6.14K 0.07% 305
2025
Q4 		$262K Buy
12,716
+7,138
+128% +$178K 0.07% 307
2025
Q3 		$96.7K Buy
5,578
+969
+21% +$19.5K 0.03% 427
2025
Q2 		$68.9K Sell
4,609
-2,742
-37% -$43K 0.02% 435
2025
Q1 		$86.1K Buy
+7,351
New +$128K 0.02% 442

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Virtus Investment Advisers's NGNE Position: Q1 2026 in Review

Virtus Investment Advisers increased its Neurogene (NGNE) stake by 2.5% in Q1 2026, buying an estimated $6.14K and bringing the position to 13,033 shares worth $263K. The position accounts for 0.07% of the portfolio, ranked #305.

Virtus Investment Advisers first reported a position in NGNE in Q1 2025 and has held it in 5 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Virtus Investment Advisers held 13,033 shares of Neurogene worth $263K as of Q1 2026.
  • Virtus Investment Advisers bought 317 Neurogene shares in Q1 2026, an estimated $6.14K.
  • Neurogene made up 0.07% of Virtus Investment Advisers's portfolio in Q1 2026, its #305 holding.
  • Virtus Investment Advisers first reported a position in Neurogene in Q1 2025 and has held it in 5 quarters since.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.